Work Here?
NeoGenomics Laboratories
Work Here?
Cancer diagnostics testing and pharma services
NeoGenomics Laboratories
Work Here?
Cancer diagnostics testing and pharma services
Overview
NeoGenomics provides cancer-focused genetic testing and information services to help diagnose and guide treatment for various cancers. Its tests include cytogenetics, FISH, flow cytometry, IHC, ISH, and molecular testing, run in CAP-accredited and CLIA-certified laboratories across multiple U.S. sites. Healthcare providers use the tests for diagnosis and treatment planning, while pharmaceutical companies use the Pharma Services division for clinical trials and drug development, with partnerships like QIAGEN for companion diagnostics. The company aims to advance oncology diagnostics and personalized medicine by delivering accurate, actionable results and supporting new cancer therapies.
About NeoGenomics Laboratories
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Fort Myers, Florida
Founded
2002
Simplify's Take
What believers are saying
- Q1 2026 revenue hit $187M, up 11%, with net loss down 34% and 2026 guidance $797-803M.
- NGS revenue grew 23% in Q4 2025, now one-third of clinical revenue at $495 per test.
- Pharma Services revenue surged 39.3% to $13M in 2020, supporting clinical trials.
What critics are saying
- Tempus AI captures NGS and MRD volumes with Tempus One platform in 6-12 months.
- Foundation Medicine's FoundationOne CDx dominance blocks PanTracer Pro reimbursement in 3-9 months.
- Natera’s Signatera undercuts RaDaR ST pricing, eroding 25% volumes in 6-12 months.
What makes NeoGenomics Laboratories unique
- NeoGenomics specializes in oncology-focused cytogenetics, FISH, flow cytometry, and molecular testing.
- RaDaR ST ctDNA assay detects MRD with 11 ppm LOD95 for solid tumors, Medicare-approved.
- Epic Aura EHR integration on April 23, 2026, enables direct test ordering in workflows.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$925.9M
Above
Industry Average
Funded Over
7 Rounds
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%NeoGenomics unveils RaDaR ST for MRD detection. NeoGenomics announced RaDaR ST, a highly sensitive ctDNA assay utilizing tumor-informed panels to detect molecular residual disease and early recurrence in various cancers, validated through extensive clinical data. March 10, 2026 NeoGenomics, Inc. announced the launch of RaDaR ST, its circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD). RaDaR ST uses patient-specific, tumor-informed panels to detect trace amounts of tumor DNA in blood, often before recurrence is visible on imaging. The assay combines whole-exome sequencing with advanced bioinformatics to track up to 48 tumor-specific variants with a limit of detection at 95% probability (LOD95) of 11 ppm, offering high sensitivity and specificity. Validated through a large and growing body of clinical and real-world data, including studies in breast and HPV-negative head and neck cancers, RaDaR ST shows utility for earlier detection of recurrence, identification of patients with persistent molecular disease, and long-term surveillance in high-risk populations. The assay is approved by Medicare for initial launch indications, with two additional indications submitted for reimbursement.
NeoGenomics has launched RaDaR ST, a circulating tumour DNA assay for detecting molecular residual disease across multiple solid tumour types. The test uses patient-specific, tumour-informed panels to detect trace amounts of tumour DNA in blood, often before recurrence appears on imaging. The assay combines whole-exome sequencing with advanced bioinformatics to track up to 48 tumour-specific variants, with a limit of detection at 95% probability of 11 parts per million. RaDaR ST has been validated through clinical studies in breast and HPV-negative head and neck cancers. Medicare has approved reimbursement for initial launch indications, with two additional indications submitted. The launch expands NeoGenomics' solid tumour testing portfolio across diagnosis, therapy selection and long-term disease monitoring.
NeoGenomics reported fourth-quarter revenue of $190 million, up 11% year-over-year, and full-year revenue of $727 million, up 10%. The company achieved its 10th consecutive quarter of positive adjusted EBITDA, reaching $13.4 million in Q4 and $43.4 million for the year. The cancer diagnostics firm is shifting away from high-volume, low-value contracts towards higher-value therapy-guided testing. NGS revenue grew 23% in Q4 and now represents approximately one-third of clinical revenue. Management expects average unit price growth to become the primary revenue driver, though volumes may compress in early 2026 during the portfolio transition. For 2026, NeoGenomics guided revenue of $793–$801 million and adjusted EBITDA of $55–$57 million. The company is launching its RaDaR ST minimal residual disease test and PanTracer Pro, with commercial momentum dependent on MolDX reimbursement decisions.
NeoGenomics has launched PanTracer Pro, a diagnostic solution designed to help clinicians make faster, more informed treatment decisions for patients with advanced-stage solid tumors. The test integrates comprehensive genomic profiling with diagnosis-directed immunohistochemistry and ancillary testing through a single coordinated order, with results available in 8–10 days. PanTracer Pro combines DNA and RNA sequencing across over 500 cancer-related genes with tumor-specific testing to support therapy selection and identify clinical trial options. When tissue samples are insufficient, cases automatically reflex to PanTracer LBx, the company's liquid biopsy assay, allowing diagnostic workup to continue without restarting the process. The Fort Myers-based company specialises in cancer genetics testing and serves oncologists, pathologists and pharmaceutical firms across the US and United Kingdom.
NeoGenomics to participate in the 44th Annual J.P. Morgan Healthcare Conference. FORT MYERS, Fla., January 05, 2026-(BUSINESS WIRE)-NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. NeoGenomics' management is scheduled to present and participate in a Q&A session on Tuesday, January 13, at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at ir.neogenomics.com. About NeoGenomics NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. View source version on businesswire.com: https://www.businesswire.com/news/home/20260105673232/en/
There are no jobs for NeoGenomics Laboratories right now.
Find jobs on Simplify and start your career today
About NeoGenomics Laboratories
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Fort Myers, Florida
Founded
2002
There are no jobs for NeoGenomics Laboratories right now.
Find jobs on Simplify and start your career today